EP3898596C0 - Pharmaceutical compound, the method of its making and use as medicinal agent - Google Patents

Pharmaceutical compound, the method of its making and use as medicinal agent

Info

Publication number: EP3898596C0
Authority: EP; European Patent Office
Prior art keywords: making; pharmaceutical compound; medicinal agent; medicinal; agent
Prior art date: 2018-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP19901248.5A

Other languages

German (de)

French (fr)

Other versions

EP3898596B1 (en

EP3898596A4 (en

EP3898596A1 (en

Inventor

Anatoliy Reder

Dmytro Pozigun

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-20

Filing date

2019-01-30

Publication date

2023-09-06

2019-01-30 Application filed by Individual filed Critical Individual

2019-01-30 Priority to RS20231130A priority Critical patent/RS64880B1/en

2019-01-30 Priority to HRP20231538TT priority patent/HRP20231538T1/en

2021-10-27 Publication of EP3898596A1 publication Critical patent/EP3898596A1/en

2022-09-28 Publication of EP3898596A4 publication Critical patent/EP3898596A4/en

2023-09-06 Application granted granted Critical

2023-09-06 Publication of EP3898596C0 publication Critical patent/EP3898596C0/en

2023-09-06 Publication of EP3898596B1 publication Critical patent/EP3898596B1/en

Status Active legal-status Critical Current

2039-01-30 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP19901248.5A 2018-12-20 2019-01-30 Pharmaceutical compound, the method of its making and use as medicinal agent Active EP3898596B1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
RS20231130A RS64880B1 (en)	2018-12-20	2019-01-30	Pharmaceutical compound, the method of its making and use as medicinal agent
HRP20231538TT HRP20231538T1 (en)	2018-12-20	2019-01-30	Pharmaceutical compound, the method of its making and use as medicinal agent

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
UAA201812659A UA119735C2 (en)	2018-12-20	2018-12-20	PHARMACEUTICAL COMPOUND, METHOD OF PREPARATION AND APPLICATION AS A MEDICINAL PRODUCT
PCT/UA2019/000020 WO2020131000A1 (en)	2018-12-20	2019-01-30	Pharmaceutical compound, the method of its making and use as medicinal agent

Publications (4)

Publication Number	Publication Date
EP3898596A1 EP3898596A1 (en)	2021-10-27
EP3898596A4 EP3898596A4 (en)	2022-09-28
EP3898596C0 true EP3898596C0 (en)	2023-09-06
EP3898596B1 EP3898596B1 (en)	2023-09-06

Family

ID=71102262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19901248.5A Active EP3898596B1 (en)	2018-12-20	2019-01-30	Pharmaceutical compound, the method of its making and use as medicinal agent

Country Status (18)

Country	Link
US (1)	US12129238B2 (en)
EP (1)	EP3898596B1 (en)
JP (1)	JP7322151B2 (en)
KR (1)	KR102709767B1 (en)
CN (1)	CN113227059B (en)
BR (1)	BR112021012071A2 (en)
CO (1)	CO2021008898A2 (en)
EA (1)	EA202090281A1 (en)
ES (1)	ES2961011T3 (en)
HR (1)	HRP20231538T1 (en)
HU (1)	HUE064344T2 (en)
IL (1)	IL284132A (en)
MX (1)	MX2021007150A (en)
PL (1)	PL3898596T3 (en)
RS (1)	RS64880B1 (en)
UA (1)	UA119735C2 (en)
WO (1)	WO2020131000A1 (en)
ZA (1)	ZA202104617B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA115205C2 (en) *	2016-10-03	2017-09-25	Товариство З Додатковою Відповідальністю "Інтерхім"	APPLICATION OF 7-BROMY-5- (O-CHLOROPHENYL) -3-PROPOXY-1,2-DIGIDRO-3H-1,4-BENZDIAZEPINE-2-ONE FOR BRAKING OF NEUROPATIC PAIN

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE621819A (en)	1961-08-29
US4432987A (en)	1982-04-23	1984-02-21	Pfizer Inc.	Crystalline benzenesulfonate salts of sultamicillin
WO1994020505A1 (en)	1993-03-12	1994-09-15	The Upjohn Company	Crystalline ceftiofur free acid
CA2457642C (en)	2001-09-26	2009-01-06	Merck & Co., Inc.	Crystalline forms of ertapenem sodium
SE0104248D0 (en)	2001-12-14	2001-12-14	Astrazeneca Ab	Method of treatment
EP1548011A1 (en)	2003-12-23	2005-06-29	Neuro3D	Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
JP2008174495A (en)	2007-01-19	2008-07-31	Reverse Proteomics Research Institute Co Ltd	Target protein and target gene for use in drug development and method for screening the same
UA108246C2 (en)	2011-05-10	2015-04-10		APPLICATION OF 3-ALCOXES-1,2-DIGIDRO-3H-1,4-BENZDIAZEPINE-2-ONET AS HIGH ACTIVE ANALGETIC AGENTS
UA115205C2 (en) *	2016-10-03	2017-09-25	Товариство З Додатковою Відповідальністю "Інтерхім"	APPLICATION OF 7-BROMY-5- (O-CHLOROPHENYL) -3-PROPOXY-1,2-DIGIDRO-3H-1,4-BENZDIAZEPINE-2-ONE FOR BRAKING OF NEUROPATIC PAIN
CN107400115A (en) *	2017-08-04	2017-11-28	正大天晴药业集团股份有限公司	A kind of new crystallization of lenalidomide and its pharmaceutical composition

2018
- 2018-12-20 UA UAA201812659A patent/UA119735C2/en unknown
2019
- 2019-01-30 US US17/415,821 patent/US12129238B2/en active Active
- 2019-01-30 ES ES19901248T patent/ES2961011T3/en active Active
- 2019-01-30 WO PCT/UA2019/000020 patent/WO2020131000A1/en active Application Filing
- 2019-01-30 JP JP2021536107A patent/JP7322151B2/en active Active
- 2019-01-30 MX MX2021007150A patent/MX2021007150A/en unknown
- 2019-01-30 EP EP19901248.5A patent/EP3898596B1/en active Active
- 2019-01-30 EA EA202090281A patent/EA202090281A1/en unknown
- 2019-01-30 PL PL19901248.5T patent/PL3898596T3/en unknown
- 2019-01-30 KR KR1020217023027A patent/KR102709767B1/en active Active
- 2019-01-30 CN CN201980085152.7A patent/CN113227059B/en active Active
- 2019-01-30 BR BR112021012071-8A patent/BR112021012071A2/en unknown
- 2019-01-30 HU HUE19901248A patent/HUE064344T2/en unknown
- 2019-01-30 RS RS20231130A patent/RS64880B1/en unknown
- 2019-01-30 HR HRP20231538TT patent/HRP20231538T1/en unknown
2021
- 2021-06-17 IL IL284132A patent/IL284132A/en unknown
- 2021-07-02 ZA ZA2021/04617A patent/ZA202104617B/en unknown
- 2021-07-06 CO CONC2021/0008898A patent/CO2021008898A2/en unknown

Also Published As

Publication number	Publication date
PL3898596T3 (en)	2024-02-26
KR102709767B1 (en)	2024-09-24
EA202090281A1 (en)	2020-08-28
UA119735C2 (en)	2019-07-25
RS64880B1 (en)	2023-12-29
WO2020131000A1 (en)	2020-06-25
HUE064344T2 (en)	2024-03-28
EP3898596B1 (en)	2023-09-06
ES2961011T3 (en)	2024-03-07
MX2021007150A (en)	2021-08-19
CO2021008898A2 (en)	2021-07-30
JP2022525579A (en)	2022-05-18
IL284132A (en)	2021-08-31
ZA202104617B (en)	2023-12-20
CN113227059B (en)	2024-08-30
JP7322151B2 (en)	2023-08-07
HRP20231538T1 (en)	2024-03-15
US12129238B2 (en)	2024-10-29
EP3898596A4 (en)	2022-09-28
US20220073474A1 (en)	2022-03-10
KR20210106538A (en)	2021-08-30
CN113227059A (en)	2021-08-06
BR112021012071A2 (en)	2021-09-21
EP3898596A1 (en)	2021-10-27

Publication	Publication Date	Title
SG11202105850YA (en)	2021-07-29	Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
IL255509B (en)	2021-04-29	Compounds as ccr2 modulators, pharmaceutical compositions comprising same and their use for the treatment of diseases
EP3675859A4 (en)	2021-06-30	Compounds, compositions, and methods for the treatment of disease
IL272446A (en)	2020-03-31	Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
PT3580208T (en)	2021-11-18	Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
IL289763A (en)	2022-03-01	Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
IL276244A (en)	2020-09-30	Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
PL3421038T3 (en)	2020-06-29	Naphthyridine compound, pharmaceutical composition and use thereof
IL276430A (en)	2020-09-30	Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
IL276290A (en)	2020-09-30	Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
IL276323A (en)	2020-09-30	4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
EP3647313A4 (en)	2021-02-17	Substituted aryl ether compound, preparation method therefor, pharmaceutical composition and use thereof
EP3456711A4 (en)	2019-10-16	Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
IL282999A (en)	2021-06-30	1,3,4-oxadiazolone compound and pharmaceutical
EP3347022A4 (en)	2019-04-03	Pharmaceutical composition including dutasteride and capsule formulation comprising the same
IL282950A (en)	2021-06-30	Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
IL284132A (en)	2021-08-31	Pharmaceutical compound, the method of its making and use as medicinal agent
IL282142A (en)	2021-05-31	4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
EP3597640A4 (en)	2020-12-16	Novel benzimidazolone compound and pharmaceutical use thereof
EP3747866A4 (en)	2021-04-07	Benzamide compound and preparation method, use, and pharmaceutical composition thereof
PT3880675T (en)	2024-12-06	Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
AU2017900496A0 (en)	2017-03-02	Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin
ZA201602037B (en)	2017-06-28	Pharmaceutical composition comprising an antiemetic agent and method for the preparation thereof

Legal Events

Date	Code	Title	Description
2019-01-30	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20231538T Country of ref document: HR
2020-07-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-09-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-09-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-10-27	17P	Request for examination filed	Effective date: 20210630
2021-10-27	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-01-14	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40052085 Country of ref document: HK
2022-03-30	DAV	Request for validation of the european patent (deleted)
2022-03-30	DAX	Request for extension of the european patent (deleted)
2022-08-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602019037143 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0243140000 Ipc: C07D0243240000 Ref country code: DE Ref legal event code: R079 Ipc: C07D0243240000
2022-09-28	A4	Supplementary search report drawn up and despatched	Effective date: 20220825
2022-09-28	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/02 20060101ALI20220819BHEP Ipc: A61K 31/5513 20060101ALI20220819BHEP Ipc: C07D 243/24 20060101AFI20220819BHEP
2023-04-17	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-04-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-05-10	INTG	Intention to grant announced	Effective date: 20230418
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230502
2023-07-28	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-08-04	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-08-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-09-06	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-09-06	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-09-27	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-09-28	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602019037143 Country of ref document: DE
2023-10-18	P04	Withdrawal of opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230911
2023-10-18	U01	Request for unitary effect filed	Effective date: 20230908
2023-10-18	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230914
2023-11-07	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2023-11-27	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20230906
2023-12-29	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20230402093 Country of ref document: GR Effective date: 20231211
2024-02-14	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 42787 Country of ref document: SK
2024-02-21	U20	Renewal fee paid [unitary effect]	Year of fee payment: 6 Effective date: 20240118
2024-03-01	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20231538T Country of ref document: HR Payment date: 20240103 Year of fee payment: 6
2024-03-07	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2961011 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240307
2024-03-15	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20231538 Country of ref document: HR
2024-03-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E064344 Country of ref document: HU
2024-04-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20240123 Year of fee payment: 6
2024-04-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106
2024-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20240116 Year of fee payment: 6 Ref country code: ES Payment date: 20240208 Year of fee payment: 6
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106
2024-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20240115 Year of fee payment: 6 Ref country code: GB Payment date: 20240118 Year of fee payment: 6 Ref country code: CH Payment date: 20240201 Year of fee payment: 6 Ref country code: SK Payment date: 20240104 Year of fee payment: 6
2024-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20240112 Year of fee payment: 6 Ref country code: NO Payment date: 20240123 Year of fee payment: 6 Ref country code: HR Payment date: 20240103 Year of fee payment: 6
2024-06-07	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602019037143 Country of ref document: DE
2024-07-12	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-07-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-08-14	26N	No opposition filed	Effective date: 20240607
2024-08-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906
2024-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906
2025-01-08	P05	Withdrawal of opt-out of the competence of the unified patent court (upc) changed	Free format text: CASE NUMBER: APP_571824/2023 Effective date: 20230914
2025-01-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20241230 Year of fee payment: 7
2025-01-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CZ Payment date: 20241230 Year of fee payment: 7
2025-01-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RO Payment date: 20241230 Year of fee payment: 7
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RS Payment date: 20241230 Year of fee payment: 7
2025-01-31	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20231538 Country of ref document: HR Payment date: 20250107 Year of fee payment: 7
2025-02-26	U20	Renewal fee paid [unitary effect]	Year of fee payment: 7 Effective date: 20250120
2025-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20250102 Year of fee payment: 7